Abstract
Bisphosphonates are stable compounds of pyrophosphoric acid that inhibit hydroxyapatite formation. This class of chemical was first investigated in the 1960s for use in the treatment of disorders of bone metabolism. Bisphosphonates have been developed for clinical use since then, and, currently, the third, nitrogen-containing, generation of bisphosphonates is widely used for the treatment of various bone diseases, including osteoporosis and bone metastases in cancer. However, despite the therapeutic benefits, the emergence of bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a growing and significant problem in a subset of patients receiving these drugs. In this review, we introduce the benefits and risks of bisphosphonates,"the light and dark side"so to speak, to facilitate a full understanding of these compounds.
| Original language | English |
|---|---|
| Pages (from-to) | 177-187 |
| Number of pages | 11 |
| Journal | Journal of Oral Biosciences |
| Volume | 51 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Jan 1 2009 |
| Externally published | Yes |
Fingerprint
All Science Journal Classification (ASJC) codes
- Medicine (miscellaneous)
- Dentistry(all)
- Biochemistry, Genetics and Molecular Biology(all)
Cite this
The light and dark side of bisphosphonates. / Jimi, Eijiro; Takami, Masamichi; Hiraga, Toru; Nakamura, Ichiro; Urade, Masahiro; Miyamoto, Yoichi.
In: Journal of Oral Biosciences, Vol. 51, No. 4, 01.01.2009, p. 177-187.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - The light and dark side of bisphosphonates
AU - Jimi, Eijiro
AU - Takami, Masamichi
AU - Hiraga, Toru
AU - Nakamura, Ichiro
AU - Urade, Masahiro
AU - Miyamoto, Yoichi
PY - 2009/1/1
Y1 - 2009/1/1
N2 - Bisphosphonates are stable compounds of pyrophosphoric acid that inhibit hydroxyapatite formation. This class of chemical was first investigated in the 1960s for use in the treatment of disorders of bone metabolism. Bisphosphonates have been developed for clinical use since then, and, currently, the third, nitrogen-containing, generation of bisphosphonates is widely used for the treatment of various bone diseases, including osteoporosis and bone metastases in cancer. However, despite the therapeutic benefits, the emergence of bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a growing and significant problem in a subset of patients receiving these drugs. In this review, we introduce the benefits and risks of bisphosphonates,"the light and dark side"so to speak, to facilitate a full understanding of these compounds.
AB - Bisphosphonates are stable compounds of pyrophosphoric acid that inhibit hydroxyapatite formation. This class of chemical was first investigated in the 1960s for use in the treatment of disorders of bone metabolism. Bisphosphonates have been developed for clinical use since then, and, currently, the third, nitrogen-containing, generation of bisphosphonates is widely used for the treatment of various bone diseases, including osteoporosis and bone metastases in cancer. However, despite the therapeutic benefits, the emergence of bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a growing and significant problem in a subset of patients receiving these drugs. In this review, we introduce the benefits and risks of bisphosphonates,"the light and dark side"so to speak, to facilitate a full understanding of these compounds.
UR - http://www.scopus.com/inward/record.url?scp=74549127194&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=74549127194&partnerID=8YFLogxK
U2 - 10.2330/joralbiosci.51.177
DO - 10.2330/joralbiosci.51.177
M3 - Review article
AN - SCOPUS:74549127194
VL - 51
SP - 177
EP - 187
JO - Journal of Oral Biosciences
JF - Journal of Oral Biosciences
SN - 1349-0079
IS - 4
ER -